Ralliant (NYSE:RAL) Coverage Initiated at BMO Capital Markets

Analysts at BMO Capital Markets began coverage on shares of Ralliant (NYSE:RAL) in a research note issued on Monday, Marketbeat Ratings reports. The firm set a “hold” rating and a $78.00 price target on the stock. BMO Capital Markets’ price target points to a potential upside of 9.63% from the company’s previous close.

RAL has been the subject of several other research reports. Vertical Research lowered shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a research report on Wednesday, May 27th. TD Cowen boosted their target price on shares of Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 20th. Wall Street Zen raised shares of Ralliant from a “hold” rating to a “buy” rating in a research note on Saturday. Royal Bank Of Canada raised their target price on shares of Ralliant from $64.00 to $71.00 and gave the stock a “sector perform” rating in a report on Thursday, July 16th. Finally, Citigroup lifted their price target on shares of Ralliant from $70.00 to $81.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $73.00.

Ralliant Stock Performance

Shares of RAL opened at $71.15 on Monday. The firm has a 50-day moving average price of $65.86 and a 200 day moving average price of $53.42. The firm has a market capitalization of $7.96 billion and a PE ratio of -6.50. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. Ralliant has a 52-week low of $37.27 and a 52-week high of $75.41.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The company had revenue of $534.60 million for the quarter. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, sell-side analysts anticipate that Ralliant will post 2.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Nolet Wealth Management LLC purchased a new stake in shares of Ralliant in the 2nd quarter valued at approximately $280,000. Wasatch Advisors LP purchased a new position in Ralliant during the 2nd quarter worth approximately $40,526,000. Mirador Capital Partners LP acquired a new stake in Ralliant during the 2nd quarter valued at $227,000. GAMMA Investing LLC raised its stake in Ralliant by 42.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,274 shares of the company’s stock valued at $94,000 after purchasing an additional 382 shares during the period. Finally, Versant Capital Management Inc lifted its holdings in shares of Ralliant by 230.1% in the second quarter. Versant Capital Management Inc now owns 604 shares of the company’s stock valued at $44,000 after purchasing an additional 421 shares in the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.